The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers
Abstract
PURPOSE: PV701, a replication-competent strain of Newcastle disease virus, causes regression of tumor xenografts after intravenous administration. This phase I study was designed to define the maximum-tolerated dose (MTD) and safety of single and multiple intravenous doses of PV701 as a single agent in patients with cancer. PATIENTS AND METHODS: Seventy-nine patients with advanced solid cancers that were unresponsive to standard therapy were enrolled. Four PV701 intravenous dosing regimens were evaluated: (1) single dose: one dose every 28 days; (2) repeat dose: three doses in 1 week every 28 days; (3) desensitizing: one lower dose followed by two higher doses in 1 week every 28 days; and (4) two week: one lower dose followed by five higher doses over 2 weeks every 21 days. RESULTS: A 100-fold dose intensification was achieved over 195 cycles. A first-dose MTD of 12 × 10 9 plaque-forming units (PFU)/m 2 was established for outpatient dosing. After an initial dose of 12 × 10 9 PFU/m 2, patients tolerated an MTD for subsequent doses of 120 × 10 9 PFU/m 2. The most common adverse events were flu-like symptoms that occurred principally after the first dose and were decreased in number and severity with each subsequent dose. Tumor site–specific adverse events and acute dosing reactions were also observed but not cumulative toxicity. Objective responses occurred at higher dose levels, and progression-free survival ranged from 4 to 31 months. Tumor tissue from one patient was obtained after 11 months of therapy and showed evidence of PV701 particles budding from the tumor cell membrane by electron microscopy and a pronounced lymphoplasmacytic infiltrate by histologic examination. CONCLUSION: PV701 warrants further study as a novel therapeutic agent for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432
Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): Mechanism of action
Gil, J., & Esteban, M. (2000) · Apoptosis · doi:10.1023/a:1009664109241 · Cited by 369
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
Chapman, P. B., Lester, T. J., Casper, E. S., Gabrilove, J. L., Wong, G. Y., Kempin, S. J., Gold, P. J., Welt, S., Warren, R. S., & Starnes, H. F. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.12.1942 · Cited by 214
Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity.
Fraker, D. L., Stovroff, M. C., Merino, M. J., & Norton, J. A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.1.95 · Cited by 196
Circulating Interferon in Mice after Intravenous Injection of Virus
Baron, S., & Buckler, C. E. (1963) · Science · doi:10.1126/science.141.3585.1061 · Cited by 160
Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.
Lorence, R. M., Katubig, B. B., Reichard, K. W., Reyes, H. M., Phuangsab, A., Sassetti, M., Walter, R. J., & Peeples, M. E. (1994) · PubMed · Cited by 156
Self-citationLorence, R. M., Rood, P. A., & Kelley, K. W. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.16.1305 · Cited by 145
Self-citationBatliwalla, F., Bateman, B. A., Serrano, D., et al. (1998) · Molecular Medicine · doi:10.1007/bf03401771 · Cited by 114
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days
Creaven, P. J., Brenner, D., Cowens, J. W., Huben, R., Wolf, R., Takita, H., Arbuck, S., Razack, M. S., & Proefrock, A. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00267953 · Cited by 81
Termeer, C., Schirrmacher, V., Bröcker, E., & Becker, J. C. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700109 · Cited by 66
Jaramillo, M., Abraham, N., & Bell, J. C. (1995) · Cancer Investigation · doi:10.3109/07357909509094468 · Cited by 41
Mouse genotype affects inducible expression of cytokine genes
Raj, N. B., Cheung, S. C., ROSZTÓCZY, I., & Pitha, P. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.6.1934 · Cited by 38
CLINICAL STUDIES EMPLOYING INTERFERON INDUCERS IN MAN AND ANIMALS *
Merigan, T. C., Clercq, E. D., Finkelatein, M. S., Clever, L. H., Walker, S. M., & Waddell, D. (1970) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1970.tb53468.x · Cited by 23
Reactions of Human Sera to Avian Adenoviruses and Newcastle Disease Virus
Miller, L. T., & Yates, V. J. (1971) · Avian Diseases · doi:10.2307/1588867 · Cited by 17
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Metadata
- Authors
- Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., & Lorence, R. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-05-01
- Volume
- 20
- Issue
- 9
- Pages
- 2251-2266
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2157408208
- Cited by
- 385
- References
- 20
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.